Bristol Myers Squibb Company
NEWS
The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.
The FDA has four target action dates this week for three supplemental approvals and one New Drug Approval.
Data from a new head-to-head study showed BMS’ Opdivo induced better progression-free survival among Hodgkin’s lymphoma patients than Seagen’s Adcetris.
ADCs from BioNTech, Daiichi Sankyo and Merck are the subject of high-profile abstracts featured at the oncology meeting, along with Merck’s late-breaking Phase III non-small cell lung cancer data.
Bristol Myers Squibb’s Reblozyl induced nearly twice the red blood cell transfusion independence compared with the current standard treatment epoetin alfa for lower-risk myelodysplastic syndrome.
Weeks after announcing a CEO shake-up and slightly decreased Q1 revenues, BMS plans to cut 48 staff members from its Princeton, NJ, facility.
After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions.
The deal could be worth more than $1 billion, starting with an upfront payment of $22.75 million.
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
JOBS
IN THE PRESS